Is HK inno.N profitable in 2025?

Yes. HK inno.N reported consolidated 2025 revenue of 1.0632 trillion won, up 19% year on year, with operating profit of 110.9 billion won, up 26% YoY, making it the eighth Korean pharma firm to join the 1 trillion won club, as of December 31, 2025.

HK inno.N is majority owned by Kolmar Korea Co., Ltd., which held approximately 43.01% of shares as of April 2026. It is publicly listed on KOSDAQ under ticker 195940 since its IPO on August 9, 2021.

Who is HK inno.N's biggest competitor?

In Korea's P-CAB drug class, HK inno.N's K-CAB competes with Daewoong's fexuprazan, Onconic/Jeil's zastaprazan, and newly entering Ildong Pharmaceutical's padofrazan (licensed December 2025). Globally, Takeda's vonoprazan is the P-CAB category originator, launched 2015.

Could AI replace HK inno.N?

No. HK inno.N's moat rests on regulatory approvals, GMP manufacturing, national reimbursement, and prescriber relationships for its patented drug K-CAB, none of which AI replaces. The company uses AI only as a discovery tool, partnering with Atommerce's CANDDIE platform for obesity candidates in April 2026.

Is K-CAB's patent facing legal risk?

HK inno.N is appealing a USPTO decision at the U.S. Court of Appeals for the Federal Circuit, with the case (No. 26-1987) filed June 30, 2026. The company previously won a second patent-infringement victory against generic K-CAB challengers by September 2024.

When will the FDA decide on K-CAB's US approval?

HK inno.N submitted a U.S. FDA New Drug Application for K-CAB in January 2026 via partner Sebela Pharmaceuticals/Braintree Laboratories, covering three GERD-related indications. A decision is expected around January 2027.

Pharma and healthcare groups · subsidiary of Kolmar Korea Co., Ltd. · South Korea

HK inno.N

Korean pharma maker of K-CAB, a top-selling heartburn drug, expanding globally.

Hard to displace

Assessed 26 July 2026 · Evidence as of 26 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 26 July 2026 · Checkable from January 2027 · Every call on the record Checkpoint: FDA decision on K-CAB's U.S. New Drug Application

The call

HK inno.N's business runs on a patented, reimbursed drug with strong Korean market share, facing competition from other approved drugs rather than from AI.

HK inno.N makes and sells medicines, particularly K-CAB, a drug that treats acid reflux and related stomach problems that has captured more than half of Korea's market for similar drugs. The company is hard to replace because its drug has government approval, insurance coverage, and a network of doctors who prescribe it, plus manufacturing expertise and relationships with global partners. Takeda makes a similar drug globally, and several Korean rivals like Daewoong and Ildong are competing for market share, so K-CAB's sales could decline if these competitors gain ground, but the bigger question is whether K-CAB stays popular in Korea and whether the company successfully gets approval and sells the drug in the United States by 2027.

Why

AI pressure: None apparent. HK inno.N uses AI tools like Atommerce's CANDDIE platform to design obesity drugs, not as a threat to its core business. Could AI do the core job? Unlikely.

Bigger players: Takeda (vonoprazan/Voquezna), plus domestic rivals Daewoong, Onconic/Jeil, and Ildong. Takeda's vonoprazan competes globally in the same P-CAB drug class; Korean rivals sell competing versions, with Ildong's padofrazan licensed but not yet launched. Could a giant copy it? No, they are blocked.

What protects it. Patent protection on K-CAB, over 50% share of Korea's P-CAB market, reimbursement status, and manufacturing scale.

What would change this call

K-CAB's Korean P-CAB market share falls below roughly 40% in quarterly data. Would show meaningful customer loss to Daewoong, Onconic/Jeil, or Ildong.
Ildong/Unovia launches padofrazan and reports early prescription volume. Would show a new direct rival actively pulling patients from K-CAB.
FDA decision on K-CAB's NDA around January 2027. Rejection would block U.S. expansion and weaken the growth story.

Key numbers

2025 revenue 1.0632 trillion won, up 19% year over year (2025-12-31)
K-CAB holds over 50% of Korea's P-CAB market (2025-12-31)
K-CAB FDA application filed January 2026, decision due ~2027 (2026-01-12)

Named risks

Heavy revenue concentration in single drug K-CAB, roughly 20% of total revenue. Severity: high
Intensifying domestic P-CAB competition as Ildong's padofrazan and rivals enter. Severity: medium
Health and Beauty division declining, Q2 2025 sales down 21.8% YoY after recall. Severity: medium
Ongoing Federal Circuit patent appeal could affect K-CAB IP protection. Severity: medium
FDA could reject or delay K-CAB NDA, stalling US market entry expected ~2027-01. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Ildong Pharmaceutical	contesting	Licensed padofrazan via subsidiary Unovia, deal closed Dec 6, 2025, entering P-CAB market
Daewoong Pharmaceutical	contesting	Fexuclue/fexuprazan competes directly against K-CAB in Korea's P-CAB market as of 2025-12
Onconic Therapeutics/Jeil Pharmaceutical	contesting	Jaqbo/zastaprazan is an active domestic P-CAB rival as of 2025-12
Takeda	gaining on	Vonoprazan launched 2015 as global P-CAB originator; K-CAB seeks US entry via FDA NDA filed 2026-01

Questions people ask

Is HK inno.N profitable in 2025?: Yes. HK inno.N reported consolidated 2025 revenue of 1.0632 trillion won, up 19% year on year, with operating profit of 110.9 billion won, up 26% YoY, making it the eighth Korean pharma firm to join the 1 trillion won club, as of December 31, 2025.
Who owns HK inno.N?: HK inno.N is majority owned by Kolmar Korea Co., Ltd., which held approximately 43.01% of shares as of April 2026. It is publicly listed on KOSDAQ under ticker 195940 since its IPO on August 9, 2021.
Who is HK inno.N's biggest competitor?: In Korea's P-CAB drug class, HK inno.N's K-CAB competes with Daewoong's fexuprazan, Onconic/Jeil's zastaprazan, and newly entering Ildong Pharmaceutical's padofrazan (licensed December 2025). Globally, Takeda's vonoprazan is the P-CAB category originator, launched 2015.
Could AI replace HK inno.N?: No. HK inno.N's moat rests on regulatory approvals, GMP manufacturing, national reimbursement, and prescriber relationships for its patented drug K-CAB, none of which AI replaces. The company uses AI only as a discovery tool, partnering with Atommerce's CANDDIE platform for obesity candidates in April 2026.
Is K-CAB's patent facing legal risk?: HK inno.N is appealing a USPTO decision at the U.S. Court of Appeals for the Federal Circuit, with the case (No. 26-1987) filed June 30, 2026. The company previously won a second patent-infringement victory against generic K-CAB challengers by September 2024.
When will the FDA decide on K-CAB's US approval?: HK inno.N submitted a U.S. FDA New Drug Application for K-CAB in January 2026 via partner Sebela Pharmaceuticals/Braintree Laboratories, covering three GERD-related indications. A decision is expected around January 2027.

Timeline

2026-07-24Analysts project Q2 2026 revenue 264.4B won, operating profit up 53% YoY
2026-06-30HK inno.N appeals USPTO decision at Federal Circuit, Case No. 26-1987
2026-05-21K-CAB cumulative prescriptions top 1 trillion won; Osong plant gets 97B won expansion
2026-04-29Kolmar Group designated large business group by Korea FTC, assets over 5T won
2026-04-27HK inno.N partners with Atommerce on AI platform CANDDIE for obesity drug candidates
2026-03-09HK inno.N reports 2025 revenue of 1.0632 trillion won, joins Korea's 1T won pharma club
2026-01-12FDA NDA filed for K-CAB via Sebela Pharmaceuticals/Braintree Laboratories
2025-12-31HK inno.N becomes RaQualia Pharma's largest shareholder, securing Japan K-CAB rights
2025-12-06Ildong Pharmaceutical licenses padofrazan via subsidiary Unovia, entering P-CAB market
2025-02-28HK inno.N opens integrated R&D hub 'HK inno.N Square' in Osong

Revision history

26 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Vertex Pharmaceuticals Tenet Healthcare Intuitive Surgical

More in Pharma and healthcare groups →

Sources

HK inno.N joins Korea's 1 trillion won pharma club (2026-03-09)
HK inno.N's K-CAB tops 1 trillion won in prescriptions (2026-05-21)
HK inno.N company history (2025-07-20)
HK inno.N ownership structure (2026-05-21)
GuruFocus market data (2026-07-26)
HK inno.N files FDA NDA for K-CAB (2026-01-12)
PitchBook HK inno.N profile
HK inno.N invests 97B won in Osong plant (2026-05-21)
HK inno.N partners with Atommerce for AI-based drug development (2026-04-27)
HK inno.N wins patent case (2024-09-20)
CAFC Case No. 26-1987 docket (2026-06-30)
Sciwind Biosciences, HK inno.N ink $5.6M deal (2024-05-07)